PNEUMOCOCCAL VACCINES MARKET ANALYSIS

Pneumococcal Vaccines Market Size and Trends

Global pneumococcal vaccines market is estimated to be valued at USD 8.92 billion in 2024 and is expected to reach USD 12.51 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 4.9% from 2024 to 2031. Increasing awareness about prevention of pneumococcal disease can boost demand for effective vaccination. The market growth is driven by expansion of immunization programs worldwide and introduction of newer and advanced vaccines to tackle serotype replacement concerns.

To learn more about this report, request sample copy

Market Driver - Increasing prevalence of pneumococcal diseases

Rising burden of pneumococcal diseases can drive the market growth. Streptococcus pneumoniae, also known as pneumococcus, is a major cause of morbidity and mortality worldwide. It is a leading cause of community-acquired pneumonia as well as other infections such as bacteremia, sepsis and meningitis, especially in children and the elderly population. Pneumonia is a significant cause of death among children under 5 years of age. According to the data published by WHO, pneumonia caused over 800,000 deaths in children under age of 5 years in 2019. Although vaccines are available to prevent pneumococcal diseases, it is still endemic in many developing and underdeveloped regions with inadequate access to vaccination and healthcare services. Even in developed nations, growing elderly population who are more vulnerable is becoming a key concern area. With aging population worldwide, the susceptibility to pneumococcal infections is projected to increase in the near future. This, coupled with emergence of antibiotic-resistant strains, has heightened the risks from these preventable diseases. Rising awareness about pneumococcal diseases and their prevention through vaccination programs boosts the need for effective pneumococcal vaccines across all regions. Growing threat posed by these infections warrants strengthened immunization efforts and availability of advanced generation vaccines to counter the global burden of pneumococcal diseases.

Advancement in vaccine technologies

Vaccine technology has witnessed tremendous progress, with new approaches enabling development of more targeted and effective vaccines. Major advancements like conjugate vaccines that stimulate improved immune response and provide longer lasting immunity have revolutionized immunization against pneumococcal diseases. Advancements like cell-culture and protein-based vaccine production platforms offer scalability and efficiency benefits over traditional cultured methods. These innovative technologies facilitate development of next generation pneumococcal vaccine formulations with broader serotype coverage and better immunogenicity. For example, second generation pneumococcal conjugate vaccines now provide protection against over 80% of disease-causing serotypes globally as compared to less than 30% coverage of earlier vaccines. Continued R&D  can expand serotype coverage and improve other attributes such as thermostability and one-dose convenience. Novel platform technologies such as protein subunit vaccines also promise better safety by avoiding live pathogens. Driven by the need for universal vaccines, new mechanisms involving polypeptide constructs and glyco-engineering are being actively pursued. With escalating antibiotic resistance challenge, vaccine innovation is increasingly being relied upon for long-term pneumococcal disease control. This augurs well for next generation pneumococcal vaccine products with capabilities beyond serotype replacement, offering even more comprehensive protection through novel mechanisms of action.